Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Financing Activities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash from Financing Activities for 4 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 98.6% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.1 million, a 96.99% decrease, with the full-year FY2024 number at $364.8 million, up 1627.29% from a year prior.
  • Cash from Financing Activities was $3.4 million for Q3 2025 at Centessa Pharmaceuticals, up from $1.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $246.0 million in Q3 2024 to a low of $12000.0 in Q2 2023.
  • A 4-year average of $28.2 million and a median of $3.0 million in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 877508.33% in 2024, then plummeted 98.6% in 2025.
  • Centessa Pharmaceuticals' Cash from Financing Activities stood at $89000.0 in 2022, then soared by 7047.19% to $6.4 million in 2023, then plummeted by 53.42% to $3.0 million in 2024, then rose by 16.0% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Cash from Financing Activities are $3.4 million (Q3 2025), $1.6 million (Q2 2025), and $3.1 million (Q1 2025).